Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LeuFectB
- Development stage
- Preclinical
- Lead developer
- University of Alberta
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
LeuFectB is a lipid-modified low molecular weight polyethyleneimine (PEI) lipopolymer designed as a delivery vehicle for short interfering RNA (siRNA) therapeutics. Developed by researchers at the University of Alberta, it is specifically optimized for the transfection of primary leukemia cells, including acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML) cells. The lipopolymer facilitates the intracellular delivery of siRNA targeting oncogenic drivers such as STAT5A, FLT3, and BCR-ABL. By downregulating these targets, LeuFectB-mediated siRNA therapy aims to reduce cell proliferation, viability, and the clonogenicity of leukemia stem cells while maintaining a favorable safety profile in non-malignant peripheral blood mononuclear cells (PBMCs).
02
Targets
ABL1 (ABL proto-oncogene 1, non-receptor tyrosine kinase)FLT3 (Fms related receptor tyrosine kinase 3)STAT5A (STAT5)
Beyond the preview
Go deeper on LeuFectB.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LeuFectB.